Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02427308|
Recruitment Status : Recruiting
First Posted : April 28, 2015
Last Update Posted : March 7, 2018
The purpose of this observational study is to fulfill FDA Post Marketing Requirement (PMR) 2127-1 for miltefosine (NDA204684): implement a pregnancy registry for the time period Mar 2015-Mar 2024.
This study is a prospective observational study in which female patients undergoing Impavido who become pregnant during treatment or within 5 months after completing treatment can volunteer to provide information about their pregnancy and the outcome of the pregnancy.
|Condition or disease||Intervention/treatment|
|Leishmaniasis or Other Uses of Miltefosine||Drug: Miltefosine|
Objective: The purpose of this observational study is to fulfill FDA Post Marketing Requirement (PMR) 2127-1 for miltefosine (NDA204684): implement a pregnancy registry for the time period Mar 2015-Mar 2024.
Study Design: This study is a prospective observational study in which female patients undergoing Impavido who become pregnant during treatment or within 5 months after completing treatment can volunteer to provide information about their pregnancy and the outcome of the pregnancy. Information will be collected from patient's provider of Impavido treatment, obstetrical treatment, and if applicable, the child's pediatrician.
Population: Leishmaniasis patients or patients who take Impavido off-label who become pregnant while taking Impavido or within 5 months after taking Impavido.
Drug name: Impavido (50 mg capsules). Dosing regimen: as per the Impavido Product Label (PL)
Study Procedures: Pregnant women will become aware of the Impavido Pregnancy Registry via the product label (PL) or the Impavido website or her physician. By calling 1-866-588-5405, the patient will be connected to the Impavido Pregnancy Registry Coordinating Center. A trained staff member will acquaint the patient with the goals and procedures of the study. If the patient tentatively agrees to participate in the study over the telephone, the patient will be mailed information forms, the Consent Form and Assent Form as appropriate, and the Consent for the patient's physician and obstetrician and the child's pediatrician to release medical information. Receipt of the four signed Consent Forms and Assent Form as appropriate by the Coordinating Center will signify patient and/or legal guardian consent/assent. The Coordinating Center will contact the patient and/or the patient's physicians each trimester until delivery to collect data on maternal adverse events (AEs), pregnancy outcome, and fetal outcome.
Sample Size And Study Duration: Estimated 0-1 patients per year for 10 years.
Maternal AEs. Pregnancy outcome. Fetal outcome.
Analysis Plan: Baseline data, compliance to prescribed treatment, and outcomes will be reported for individual patients and for all patients.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||2 participants|
|Target Follow-Up Duration:||9 Months|
|Official Title:||Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry|
|Actual Study Start Date :||July 2015|
|Estimated Primary Completion Date :||March 2025|
|Estimated Study Completion Date :||March 2026|
|miltefosine patients that become pregnant||
target dose = 2.5 mg/kg/day for 28 days
- number of patients with adverse effects during pregnancy [ Time Frame: 9 months ]
- number of patients with adverse pregnancy outcome [ Time Frame: 9 months ]
- number of patients with adverse fetal outcome [ Time Frame: at birth ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02427308
|Contact: Katerina Ujhazy, MDemail@example.com|
|United States, Maryland|
|North Potomac, Maryland, United States|
|Contact: J Ransom|
|Principal Investigator:||Janet Ransom, PhD||Fast Track Drugs and Biologics LLC|